Collegium Pharmaceutical, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing condensed consolidated financial statements and management discussion for the third quarter.

Key Highlights

  • Total assets: The company reported total assets of $2,095,936 thousand as of September 30, 2026, up from $1,656,834 thousand as of December 31, 2025.
  • Cash and cash equivalents: Cash and cash equivalents stood at $144,797 thousand as of September 30, 2026, compared to $231,252 thousand at December 31, 2025.
  • Intangible assets: Intangible assets, net, increased to $1,134,549 thousand from $669,510 thousand at year-end 2025.
  • Goodwill: Goodwill rose to $193,885 thousand from $145,925 thousand at December 31, 2025.
  • Accounts receivable: Accounts receivable, net, increased to $310,785 thousand from $211,328 thousand at year-end 2025.
  • Shares outstanding: As of October 31, 2026, there were 31,075,424 shares of Common Stock outstanding.
  • Accrued rebates, returns and discounts: This liability grew to $427,164 thousand from $318,266 thousand at December 31, 2025.

Collegium Pharmaceutical Balance Sheet Shifts in Q3 2026

According to the filing, Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a Virginia-incorporated pharmaceutical company headquartered in Stoughton, Massachusetts, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The registrant is classified as a large accelerated filer and confirmed it is not a shell company.

The condensed consolidated balance sheet disclosed total current assets of $611,751 thousand as of September 30, 2026, compared to $691,411 thousand at December 31, 2025. The filing noted that marketable securities, which stood at $155,427 thousand at year-end 2025, fell to zero by September 30, 2026. Inventory increased to $88,202 thousand from $40,912 thousand over the same period. Restricted cash, reported across both current and noncurrent categories, totaled $19,850 thousand (current) and $1,062 thousand (noncurrent) as of September 30, 2026.

On the liabilities side, total current liabilities reached $603,085 thousand as of September 30, 2026, up from $440 thousand disclosed as the partial figure in the filing for December 31, 2025. The current portion of term notes payable increased to $60,500 thousand from $29,000 thousand. A current portion of contingent consideration of $13,308 thousand appeared on the September 30, 2026 balance sheet, compared to zero at year-end 2025. The filing also noted business combination consideration payable of $17,565 thousand at both dates. The company's deferred tax assets grew to $126,246 thousand from $112,539 thousand. The filing contains forward-looking statements that, according to the company's own cautionary language, "are not guarantees of performance" and are subject to risks and uncertainties described in the Risk Factors section.

What Was Disclosed

Collegium Pharmaceutical filed its Q3 2026 Form 10-Q covering the period ended September 30, 2026, disclosing unaudited condensed consolidated balance sheet data, management discussion, and updated risk factors, with 31,075,424 shares outstanding as of October 31, 2026.